Beispiel: Heart Attack

Suchen Sie in klinischen Studien nach: Iodine-131 anti-B1 antibody

Insgesamt 53 ergebnisse

NCT00992758

Abgeschlossen

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

Bedingungen: Lymphoma, Non-Hodgkin
NCT01868035

Abgeschlossen

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Bedingungen: Lymphoma, Non-Hodgkin
NCT00938041

Abgeschlossen

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Bedingungen: Lymphoma, Non-Hodgkin
NCT00996996

Abgeschlossen

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Bedingungen: Lymphoma, Non-Hodgkin
NCT00135200

Aktiv, nicht rekrutierend

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

Bedingungen: Multiple Myeloma
NCT00484874

Abgeschlossen

Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Bedingungen: Hodgkin's Disease
NCT01663714

Abgeschlossen

Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.

Bedingungen: Lymphoma, Non-Hodgkin
NCT00992992

Abgeschlossen

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Bedingungen: Lymphoma, Mantle-Cell
NCT00950755

Abgeschlossen

Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

Bedingungen: Lymphoma, Non-Hodgkin
NCT01573000

Abgeschlossen

A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

Bedingungen: Lymphoma, Non-Hodgkin
NCT00022958

Unbekannter Status

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Bedingungen: Non-Hodgkin's Lymphoma
NCT00996593

Abgeschlossen

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Bedingungen: Lymphoma, Non-Hodgkin
NCT01224821

Abgeschlossen

Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies

Bedingungen: Lymphoma, Non-Hodgkin
NCT00004874

Beendet

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Bedingungen: Lymphoma
NCT00022893

Unbekannter Status

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Bedingungen: Non-Hodgkin's Lymphoma
NCT00022906

Unbekannter Status

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Bedingungen: Non-Hodgkin's Lymphoma
NCT00022932

Unbekannter Status

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Bedingungen: Non-Hodgkin's Lymphoma
NCT00574509

Abgeschlossen

BEAM+131I-Anti-B1 & Autologous Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

Bedingungen: Lymphoma
NCT01389076

Beendet

Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Bedingungen: Follicular Lymphoma
NCT00022880

Unbekannter Status

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Bedingungen: Chronic Lymphocytic Leukemia
NCT00476047

Abgeschlossen

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Bedingungen: Lymphoid Leukemia in Remission; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma
NCT00268983

Abgeschlossen

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Bedingungen: Lymphoma, Non-Hodgkin
NCT00329030

Abgeschlossen

Rituxan vs Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (BMT CTN 0401)

Bedingungen: Lymphoma, B-Cell; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin
NCT00989664

Abgeschlossen

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Bedingungen: Lymphoma, Non-Hodgkin
NCT00933335

Abgeschlossen

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Bedingungen: Lymphoma, Non-Hodgkin